Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Neoadjuvant and Postoperative Treatment With Dabrafenib and Trametinib in BRAF Mutated Papillary Craniopharyngioma

NCT05525273 is registered in ClinicalTrials.gov with Eva Marie Erfurth, MD, PhD as lead sponsor.

NCT NCT05525273
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05525273 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Neoadjuvant and Postoperative Treatment With Dabrafenib and Trametinib in BRAF Mutated Papillary Craniopharyngioma
Lead sponsor
Eva Marie Erfurth, MD, PhD
Phase
Phase 2
Overall status
Recruiting
Start date
September 1, 2023
Completion date
April 10, 2028
Enrollment
25 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

craniopharyngioma